Based in Copenhagen, Denmark, with North American operations based in Fairfax, Virginia, Immudex is the sole proprietor of DNA barcoded MHC multimer technology. The dCODE Dextramer? technology is an advanced development of Immudex proprietary MHC Dextramer? reagents, which are superior for the detection of antigen-specific T cells. The dCODE? technology enables massive multiplexing of disease-specific T-cell detection overcoming the limitations of earlier technologies. Find out more at www.immudex.com.